Navigation Links
Hospira Joins the Generic Pharmaceutical Association
Date:2/23/2012

LAKE FOREST, Ill., Feb. 23, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today that it has joined the Generic Pharmaceutical Association (GPhA). Hospira is dedicated to Advancing Wellness, a goal that matches well with the GPhA's core purpose of bringing affordable medications to patients who need them.

"Hospira is pleased to announce our membership in the GPhA today," said Thomas Moore, president, U.S., Hospira. "We commend the leadership shown by GPhA President Ralph Neas and the excellent staff he has assembled. GPhA is a strong industry trade association that will continue to work tirelessly to bring the safest, high-quality, lower-cost generic drugs to patients and families who need them, and Hospira looks forward to working with the association on the many pressing issues facing our industry."

"We are pleased to welcome Hospira to GPhA, and we look forward to their joining in the Association's mission to improve the lives of consumers by providing timely access to affordable pharmaceuticals," said Ralph G. Neas, President and CEO of GPhA. "Hospira's products, like those of all our members, have enabled millions of Americans to obtain affordable treatments for critical conditions. Their input and participation will be a valuable asset for GPhA as we move into this new and exciting time for our industry."

As the leading provider of generic injectables in the United States with the broadest and deepest portfolio of low-cost, safe and effective products, Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. Therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About GPhA

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 78 percent of the prescriptions dispensed in the United States but consume just 25 percent of the total drug spending. Additional information is available at gphaonline.org.

About Hospira

Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Works With FDA to Help Avert Methotrexate Shortage; Shipping One Months Supply of New Product Immediately and on Track to Ensure Sustainable Supply
2. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
3. Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections
4. Hospira to Present at the J.P. Morgan 30th Annual Healthcare Conference Jan. 10, 2012
5. Hospira Reports Third-Quarter 2011 Results
6. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
7. Hospira to Host Conference Call for Third-Quarter 2011 Results
8. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
9. Hospira to Host 2011 Investor Day
10. Hospira to Present at the Morgan Stanley Global Healthcare Conference
11. Hospira Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are ... BCC Research reveals in its new report that markets in ... see strong growth due to rising government healthcare spending, increased levels of ... Continue Reading ... ...
(Date:1/23/2017)... Spain , January 23, 2017 ... clinical-stage biopharmaceutical company focused on treatments for calcification ... been enrolled in the Phase IIb "CaLIPSO Study" ... treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) ... patients, in the last stage of chronic kidney ...
(Date:1/22/2017)... , Saudi Arabia , January 22, 2017 ... US and UAE discuss ... , at the World Economic Forum   "The management ... by big data and powered by artificial intelligence and this trend is going ... the ,Hospital of the Future, at the concluding day of the 47 th ...
Breaking Medicine Technology:
(Date:1/23/2017)... Switzerland (PRWEB) , ... January 23, 2017 , ... ... lab and production applications. However, choosing the right method is paramount to success. ... occur more often in situations where multiple persons use the same equipment. Rare ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... providing high-quality general gynecological care and gynecological services for women of ... personalized care for a wide variety of reproductive services from routine health screenings ...
(Date:1/23/2017)... ... 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating and ... Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the third ... a preacher for over nineteen, a pastor for over fifteen years. He is a ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals ... of a simple test will take days to arrive to the end customer, having ... direct access to their lab tests, bypassing the cost and delay of traditional means. ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites ... isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the ... key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear ...
Breaking Medicine News(10 mins):